Biotek-snakken — Oktober 2021
-
Photocure:Full publication from U.S. registry now available, highlighting the Role of Blue Light Cystoscopy in Detecting Invasive Bladder Tumor.https://photocure.com/news/full-publication-from-u.s.-registry-now-available-highlighting-the-role-of-blue-light-cystoscopy-in-detecting-invasive-bladder-tumor/
-
Nordic Nanovector:Nordic Nanovector ASA (OSE: NANOV) is pleased to announce that it has entered into a research collaboration with the University of Pennsylvania ("Penn") to generate a CD37-targeting CAR-T cell approach as a potential treatment for patients with B-cell malignancieshttps://www.nordicnanovector.com/investors-and-media/press-releases?page=/press/perma/1955736
-
Atea Pharmaceuticals skuffer med middel mod covid-19 og falder 70 pct.
https://www.proinvestor.com/investornyt/719889/atea-pharmaceuticals-skuffer-med-middel-mod-covid-19-og-falder-70-pct -
Best Health Care Stocks To Buy In Q4? 4 For Your Watchlist https://www.proinvestor.com/investornyt/720774/best-health-care-stocks-to-buy-in-q4-4-for-your-watchlist
-
Derfor er biotekaktier shortsælgerne yndlingsoffer https://www.proinvestor.com/index.php?p=debat_1&postid=97968
-
Storinvestor i Hansa Biopharma har endnu engang øget ejerandelen fremgår det i q3 regnskabet
-
BrainCool AB (publ) – Nordisk studie med Cooral
System accepterad för publicering -
for dem af jer som følger denne
-
Lige for at følge op for i en forecast på TTM markedet frem til 2026. https://uk.news.yahoo.com/temperature-management-market-projected-reach-083600409.html
-
Entasis: Zoli ph3 har fået forlænget Primary Completion Date til June 30 2023 https://www.clinicaltrials.gov/ct2/show/NCT03959527 @Bioshare, har du set en update på, om der stadig forventes topline data inden for få uger? Inva kv. rapport i næste uge og Entasis ugen efter, kan blive lidt interessant både mht Zoli dato og evt øgning af Invas aktiebeholdning i Entasis.
-
DevOp jeg ved det faktisk ikke...beklager Jeg vil gætte på at de data er forsinket, og altså ikke kommer i år. Aktiekursen er godt nok svær at læse kortsigtet - men er selvsagt meget tilfreds med udfaldet af SUL-DUR. Innoviva styrer showet her ingen tvivl om det....og disker helt sikkert op med mere cash (men også udvanding). Men forventer alligevel en mangedobling af kursen fra dette niveau. Muligt det ikke sker...
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind